EFSA Assessment: Tomato Extract Health Claims

Guires Food Research Lab > Uncategorised  > EU Regulations  > EFSA Assessment: Tomato Extract Health Claims
W12 (1) (1)

EFSA Assessment: Tomato Extract Health Claims

Substances that serve as possible antiplatelet factors were discovered in water-soluble tomato concentrate (WSTC). These factors have been shown to inhibit platelet aggregation. Platelet aggregation has been shown to play a role in developing plaques in the walls of blood vessels, which contributes to the pathogenesis of cardiovascular disease. WSTC could be safe platelet inhibitor for individuals with platelet hyperactivity who are at the risk for developing cardiovascular disease.

In 2010, the European Food Safety Authority (EFSA) carried out an assessment of health claims related to a water-soluble tomato concentrate, types I and II, which are available in the form of powder, tablets and capsules.

  • The results of an unpublished study revealed that tomato extract had beneficial effects on blood platelet aggregation, which could potentially reduce the risk of cardiovascular disease, and there were significant differences between the types of tomato extract that caused a reduction in platelet aggregation.

However, EFSA concluded that there was insufficient evidence to support this claim and that the evidence provided by the manufacturer was not of sufficient quality to demonstrate a cause-and-effect relationship between the consumption of the extract and the claimed health benefits. As a result, the claim was not authorized for use on products containing the extract in the EU market [1].

admin
No Comments

Sorry, the comment form is closed at this time.